A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies

The PI3K pathway may be a potential mechanism to overcome cisplatin resistance. We conducted a phase Ib trial of alpelisib and cisplatin for patients with solid tumor malignancies with planned dose expansion in HPV-associated tumors. The primary objective was to determine the MTD and recommended pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsang, Erica S., Aggarwal, Rahul R., Dhawan, Mallika S., Bergsland, Emily K., Alvarez, Edwin A., Calabrese, Susan, Pacaud, Romain, Garcia, Jose, Fattah, Delaire, Thomas, Scott, Grabowsky, Jennifer, Moasser, Mark M., Munster, Pamela N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010328/
https://www.ncbi.nlm.nih.gov/pubmed/36923283
http://dx.doi.org/10.1158/2767-9764.CRC-22-0028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010328/
https://www.ncbi.nlm.nih.gov/pubmed/36923283
http://dx.doi.org/10.1158/2767-9764.CRC-22-0028

Ejemplares similares